Investigating how specific cell signaling affects blood clot formation
Official title: The Role of Gab2-MALT1-mediated cell signaling in venous thrombogenesis
Funded at University of Texas Hlth Ctr at Tyler · NIH-11138576 · Data updated 2026-11-12
This study is looking into how inflammation causes blood clots in conditions like deep vein thrombosis and pulmonary embolism, with the hope of finding new ways to treat these issues safely and effectively, so patients can have better options with less risk of bleeding.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Ctr at Tyler NIH-funded |
| Lab location | 1 site (Tyler, United States) |
| Project start | July 15, 2024 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $613,716 |
| NIH project number | 5R01HL170945-02 |
| Project ID | NIH-11138576 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for venous thromboembolism, including those with a history of deep vein thrombosis or pulmonary embolism.
✕Less likely to help
Patients who do not have risk factors for venous thromboembolism or those already effectively managed with current anticoagulant therapies may not benefit from this research.
What this research studies
This research focuses on understanding the mechanisms behind venous thromboembolism (VTE), which includes conditions like deep vein thrombosis and pulmonary embolism. By studying the role of Gab2, a signaling protein in endothelial cells, the research aims to uncover how inflammation contributes to blood clot formation. The goal is to identify new therapeutic targets that could lead to safer and more effective treatments for VTE, reducing the risks associated with current anticoagulant therapies. Patients may benefit from insights that could lead to innovative treatment options that minimize bleeding risks.
Why it matters
Potential benefit: If successful, this research could lead to the development of safer and more effective treatments for venous thromboembolism.
How similar studies have gone: Other research has shown promise in targeting inflammatory pathways to prevent thromboembolism, suggesting that this approach may yield significant advancements.
Where this research is happening
-
University of Texas Hlth Ctr at Tyler
Tyler, United States Active
Researchers
- Principal investigator: Lella, Vijaya Mohan Rao — University of Texas Hlth Ctr at Tyler
- Study coordinator: Lella, Vijaya Mohan Rao
Related research
Other NIH-funded projects on the same topics.
-
Lipid damage and a form of cell death that turns on blood clotting
This grant explores how certain lipid byproducts and inflammatory cell death trigger tissue factor to start dangerous blood clots, with the aim of finding targets to prevent clot-related heart and vessel problems.
-
Targeting Runx3 to treat a serious immune disease in children
A new approach aims to help kids with a dangerous immune condition by targeting Runx3 to calm overactive immune cells.
-
Southwest Center for Agricultural Health, Injury Prevention, and Education
A regional center partner network is working to improve safety and health for agricultural workers and their communities through research, outreach, and translation of best practices.
-
Understanding how coronavirus spike proteins change shape to enter cells
A study to better understand how spike proteins on enveloped viruses change shape over time to help viruses enter cells and how antibodies recognize them.
-
Targeting inflammation and clot breakdown to boost empyema treatment
A patient-focused study tests a low-dose alteplase plus an inflammation-blocking peptide to improve drainage and survival for adults with empyema who can’t undergo surgery.
-
Gab2-MALT1 signaling and venous clots: a new path to safer therapies
A doctor-scientist team is studying how a specific cell signaling pathway (Gab2-MALT1) contributes to venous clots, with the aim of finding safer ways to prevent and treat them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.